News & analysis on the clinical development and manufacture of large molecule drugs
By Natalie Morrison
- Last updated on
Pavliska – who was in the original group of scientists who started Galapogos NV – was director of business development with AMRI.
In her new role for the Norwegian-based oncology biopharma, she will prepare for the commercialization of the company’s proprietary novel EMT (epithelial -mesenchymal cancer targets).
BerGenBio CEO Richard Godfrey said: “We hope to utilize both Heidi’s extensive network and industry experience as we widen access to the CellSellect technology platform and build risk-sharing development programs in the industry.”